Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2019-06-28 Regulatory Filings
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the securities to be registered, the plans under which they are issued, and legal and indemnification information. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual registration statement filing.
2019-06-28 English
Regulatory Filings 2019
Regulatory Filings
2019-06-18 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a letter from Novus Therapeutics, Inc. to the SEC requesting acceleration of the effective time for a Registration Statement on Form S-1. It references the filing of the Form S-1 and requests an administrative action related to the registration statement. The document is short (1109 characters) and does not contain financial data or report content itself. It is an official regulatory communication related to a filing but not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-06-14 English
Regulatory Filings 2019
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. The text does not contain any officer certifications or attestations. Given the lack of identifiable information and the fallback rule for documents that do not neatly fit into any specific category, the appropriate classification is Regulatory Filings (RNS). The confidence is moderate due to the inability to extract meaningful content but the clear absence of any other identifiable filing type.
2019-06-12 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being registered, the company, risk factors, use of proceeds, and other disclosures typical of an initial or secondary public offering registration. This is not an annual report, earnings release, or any other type of financial or governance report. It is a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, supporting a high confidence level.
2019-06-07 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.